9
NTRK First-line
Recommendation 13.1
➤ For patients with an NTRK fusion, a performance status of 0–2,
previously untreated NSCLC, clinicians may offer entrectinib or
larotrectinib (Moderate recommendation; IC-L).
Recommendation 13.2
➤ For patients with an NTRK fusion, a performance status of 0–2,
previously untreated NSCLC, clinicians may offer standard therapy
based on the ASCO/OH non-driver mutation guideline (Moderate
recommendation; IC-L).
NTRK Second-line
Recommendation 14.1
➤ For patients with an NTRK fusion, if NTRK-targeted therapy was not
given in the first-line setting, clinicians may offer standard therapy
based on the ASCO/OH non-driver mutation guideline (Moderate
recommendation; IC-L).
Recommendation 14.2
➤ For patients with an NTRK fusion previously treated NSCLC who have
not received an NTRK inhibitor, clinicians may offer entrectinib or
larotrectinib (Moderate recommendation; IC-L).
